186 related articles for article (PubMed ID: 16360477)
1. Analysis of membrane-bound complement regulatory proteins in prostate cancer.
Loberg RD; Wojno KJ; Day LL; Pienta KJ
Urology; 2005 Dec; 66(6):1321-6. PubMed ID: 16360477
[TBL] [Abstract][Full Text] [Related]
2. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
Fishelson Z; Donin N; Zell S; Schultz S; Kirschfink M
Mol Immunol; 2003 Sep; 40(2-4):109-23. PubMed ID: 12914817
[TBL] [Abstract][Full Text] [Related]
3. Complement-binding proteins are strongly expressed by human preimplantation blastocysts and cumulus cells as well as gametes.
Taylor CT; Johnson PM
Mol Hum Reprod; 1996 Jan; 2(1):52-9. PubMed ID: 9238658
[TBL] [Abstract][Full Text] [Related]
4. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues.
Thorsteinsson L; O'Dowd GM; Harrington PM; Johnson PM
APMIS; 1998 Sep; 106(9):869-78. PubMed ID: 9808413
[TBL] [Abstract][Full Text] [Related]
5. Expression of complement regulatory proteins [membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59)] in endometrial stressed cells.
Iborra A; Mayorga M; Llobet N; Martínez P
Cell Immunol; 2003 May; 223(1):46-51. PubMed ID: 12914757
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
[TBL] [Abstract][Full Text] [Related]
7. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
Weng WK; Levy R
Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
[TBL] [Abstract][Full Text] [Related]
8. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours.
Schmitt CA; Schwaeble W; Wittig BM; Meyer zum Büschenfelde KH; Dippold WG
Eur J Cancer; 1999 Jan; 35(1):117-24. PubMed ID: 10211099
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.
Zell S; Geis N; Rutz R; Schultz S; Giese T; Kirschfink M
Clin Exp Immunol; 2007 Dec; 150(3):576-84. PubMed ID: 17903221
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma.
Gelderman KA; Kuppen PJ; Bruin W; Fleuren GJ; Gorter A
Eur J Immunol; 2002 Jan; 32(1):128-35. PubMed ID: 11754353
[TBL] [Abstract][Full Text] [Related]
12. The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.
Kesselring R; Thiel A; Pries R; Fichtner-Feigl S; Brunner S; Seidel P; Bruchhage KL; Wollenberg B
Eur J Cancer; 2014 Aug; 50(12):2152-61. PubMed ID: 24915776
[TBL] [Abstract][Full Text] [Related]
13. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.
Sohn JH; Kaplan HJ; Suk HJ; Bora PS; Bora NS
Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3492-502. PubMed ID: 11006244
[TBL] [Abstract][Full Text] [Related]
14. Human nasal epithelium adsorbs complement C3-related fragments and expresses cell membrane complement regulatory proteins.
Varsano S; Frolkis I; Shapiro H; Ophir D
Laryngoscope; 1996 May; 106(5 Pt 1):599-604. PubMed ID: 8628088
[TBL] [Abstract][Full Text] [Related]
15. Expression of complement regulatory proteins on islets of Langerhans: a comparison between human islets and islets isolated from normal and hDAF transgenic pigs.
Bennet W; Björkland A; Sundberg B; Brandhorst D; Brendel MD; Richards A; White DJ; Nilsson B; Groth CG; Korsgren O
Transplantation; 2001 Jul; 72(2):312-9. PubMed ID: 11477359
[TBL] [Abstract][Full Text] [Related]
16. Complement-regulatory proteins in ovarian malignancies.
Bjørge L; Hakulinen J; Wahlström T; Matre R; Meri S
Int J Cancer; 1997 Jan; 70(1):14-25. PubMed ID: 8985085
[TBL] [Abstract][Full Text] [Related]
17. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD97 and CD55 in human medullary thyroid carcinomas.
Mustafa T; Klonisch T; Hombach-Klonisch S; Kehlen A; Schmutzler C; Koehrle J; Gimm O; Dralle H; Hoang-Vu C
Int J Oncol; 2004 Feb; 24(2):285-94. PubMed ID: 14719104
[TBL] [Abstract][Full Text] [Related]
19. Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation.
van Beek J; van Meurs M; 't Hart BA; Brok HP; Neal JW; Chatagner A; Harris CL; Omidvar N; Morgan BP; Laman JD; Gasque P
J Immunol; 2005 Feb; 174(4):2353-65. PubMed ID: 15699172
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of membrane inhibitors of complement in human gastric epithelium during Helicobacter-associated gastritis.
Sasaki M; Joh T; Tada T; Okada N; Yokoyama Y; Itoh M
Histopathology; 1998 Dec; 33(6):554-60. PubMed ID: 9870151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
